In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stereotaxis: When the Hammer Finds the Nail

Executive Summary

Stereotaxis began as a research project--developing a magnetic surgical guidance system--that serendipitously became a company without much regard for commercial prospects. The original design was ahead of the technology curve, but innovations in magnetic and imaging systems fortuitously enabled Stereotaxis to turn this concept into a product. The company's system, however, was and still remains far ahead of the necessary adjunctive drugs and devices necessary to become a viable therapeutic tool in neurology, the area Stereotaxis first sought to pursue. Looking for applications in other specialties for what it believes is a platform technology, Stereotaxis shifted its focus to cardiology. The company launched a system that has been well-received in the small but growing area of electrophysiology. Most recently, Stereotaxis has begun to focus on what could be its most significant opportunity: interventional cardiology. Here, too, the company appears to be the beneficiary of good timing: in the era of drug-eluting stents, interventionalists are likely to treat more difficult patients, the cases that could benefit most from Stereotaxis' advanced guidance system. The company's system, however, was and still remains far ahead of the adjunctive drugs and devices necessary to become a viable therapeutic tool in neurology, the area Stereotaxis first sought to pursue.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002209

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel